Depressive illness, generalised anxiety disorder
MHRA Drug Safety Update - Duloxetine: regular assessment for suicidal ideation
Central nervous system
LSCMMG is adopting the local decision made prior to April 2013
Reason for decision: The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.
Reason for decision:
Suitable for initiation in primary care